Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 286

Results For "US"

9619 News Found

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7
News | April 08, 2026

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle


Trialt and Viedoc team up to transform clinical trials
Clinical Trials | April 08, 2026

Trialt and Viedoc team up to transform clinical trials

The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide


IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals
Digitisation | April 08, 2026

IndiaAI, CDSCO launch hackathon to accelerate health innovation approvals

AI challenge offers Rs 10 lakh top prize and potential ?50 lakh deployment contract; applications open till April 17


Transgene and NEC join forces to advance personalized cancer vaccine
R&D | April 08, 2026

Transgene and NEC join forces to advance personalized cancer vaccine

TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor


Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health
News | April 08, 2026

Regeneron and TriNetX forge $200M partnership to supercharge drug discovery and digital health

TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners


WHO updates global guidelines to combat opioid crisis
Healthcare | April 08, 2026

WHO updates global guidelines to combat opioid crisis

Opioid dependence remains a major driver of death and disease worldwide


OneCyte and Kemp Proteins to revolutionize cell line development
Biopharma | April 08, 2026

OneCyte and Kemp Proteins to revolutionize cell line development

Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules


Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion
News | April 08, 2026

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion

The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio